HTFL vs LNTH
HTFL: HeartFlow uses AI-powered software to transform standard cardiac scans into actionable 3D insights for non-invasive coronary artery disease diagnosis and treatment planning. LNTH: Lantheus Holdings is a medical technology leader specializing in diagnostic imaging and targeted radiopharmaceutical therapies for oncology and cardiovascular care.
Side-by-side fundamentals
| Metric | HTFL | LNTH | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $25.37 | $101.00 | |
| Market cap as of 2026-08-01 | $2.2B | $6.5B | |
| P/E as of 2026-08-01 | n/a | 23.34 | |
| PEG as of 2026-08-01 | n/a | 1.38 | |
| Net margin as of 2026-08-01 | -58.4% | +18.1% | LNTH higher |
| Gross margin as of 2026-08-01 | +78.1% | +60.5% | HTFL higher |
| Operating margin as of 2026-08-01 | -43.1% | +22.6% | LNTH higher |
| ROE as of 2026-08-01 | -38.9% | +24.3% | LNTH higher |
| ROA as of 2026-08-01 | -36.4% | +12.4% | LNTH higher |
| Debt / equity as of 2026-08-01 | 0.00 | 0.47 | HTFL lower |
| Revenue growth (YoY) as of 2026-08-01 | +41.3% | +0.6% | HTFL higher |
| Revenue CAGR (3y) SEC XBRL | +42.1% | +18.1% | HTFL higher |
| Beta as of 2026-08-01 | 2.00 | -0.01 | |
| 1-year return as of 2026-07-30 close | n/a | +40.6% |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.